Notably, studies have shown that EGFR in GBM frequently exhibits gene amplification (∼50% of cases) or mutations (e.g., EGFRvIII), leading to constitutive activation of its signaling pathway with distinct regulatory mechanisms compared to other tumors [45]. This evidence concerns the gene EGFR and glioblastoma.